← Leaderboards
Maria G Castro
University Of Michigan At Ann Arbor
$22,126,725
Attributed
$26,125,038
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,125,038 · 17
By mechanism
R01$14,481,726 · 7
R37$3,597,467 · 2
U01$3,076,736 · 1
T32$2,842,936 · 1
R21$1,680,387 · 4
P30$343,394 · 1
Top collaborators
- Joerg Lahann7 shared
- James J. Moon7 shared
- Analisa Virginia Difeo4 shared
- David Benner Lombard3 shared
- Elizabeth R Lawlor1 shared
- Anna Schwendeman1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- James J. Moon$14,172,333
- Elizabeth R Lawlor$9,932,316
- Lam Cheung Tsoi$2,502,429
- Ashley Melnick$91,535
- Pedro R Lowenstein$13,187,884
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneTumorGliomaMediatingResponseCellsOperative Surgical ProceduresMalignant Neoplasm Of BrainImmune ResponseTreatment EfficacyIn VivoBrainGlioblastomaNeoplastic CellRadiation TherapyBrain NeoplasmsStandard Of CareMutationExhibitsTumor MicroenvironmentCytotoxicMolecularGene TherapyT-Lymphocyte
Grant awards (74)
Neuro-immune mechanisms in mutant IDH1 gliomas$659,325
R37 · FY2025 · NS · contact PI
Novel nano-vaccine technology for inducing immunity against gliomas$501,930
R01 · FY2025 · NS
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics$470,970
R01 · FY2025 · NS
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.$457,838
R01 · FY2025 · NS · contact PI
Training Program in Tumor Microenvironment$347,050
T32 · FY2025 · CA · contact PI
Immunologic Monitoring (IM)$116,613
P30 · FY2025 · CA · contact PI
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics$95,458
R01 · FY2025 · NS
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.$494,713
R01 · FY2024 · NS · contact PI
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics$462,077
R01 · FY2024 · NS
Novel nano-vaccine technology for inducing immunity against gliomas$404,744
R01 · FY2024 · NS
Training Program in Tumor Microenvironment$389,532
T32 · FY2024 · CA · contact PI
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics$120,789
R01 · FY2024 · NS
Immunologic Monitoring (IM)$112,168
P30 · FY2024 · CA · contact PI
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics (Supplement)$25,331
R01 · FY2024 · NS
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.$526,149
R01 · FY2023 · NS · contact PI
Novel nano-vaccine technology for inducing immunity against gliomas$501,930
R01 · FY2023 · NS
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics$481,602
R01 · FY2023 · NS
Immunologic Monitoring (IM)$114,613
P30 · FY2023 · CA · contact PI
Novel nano-vaccine technology for inducing immunity against gliomas$84,667
R01 · FY2023 · NS
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.$527,929
R01 · FY2022 · NS · contact PI
Novel nano-vaccine technology for inducing immunity against gliomas$501,930
R01 · FY2022 · NS
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics$486,665
R01 · FY2022 · NS
Cancer Biology Training Program$389,145
T32 · FY2022 · CA · contact PI
Administrative Diversity Supplement- Novel Nano-Vaccine Technology for Inducing Immunity Against Gliomas$84,667
R01 · FY2022 · NS
Novel nano-vaccine technology for inducing immunity against gliomas$501,930
R01 · FY2021 · NS
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics$496,508
R01 · FY2021 · NS · contact PI
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies$443,645
R37 · FY2021 · NS · contact PI
Chemo-immunotherapy strategy for pediatric high grade glioma$429,000
R21 · FY2021 · NS · contact PI
Cancer Biology Training Program$365,397
T32 · FY2021 · CA · contact PI
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies$443,645
R37 · FY2020 · NS · contact PI
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics$420,701
R01 · FY2020 · NS · contact PI
Cancer Biology Training Program$359,608
T32 · FY2020 · CA · contact PI
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics$52,009
R01 · FY2020 · NS · contact PI
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics$456,274
R01 · FY2019 · NS · contact PI
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies$443,645
R37 · FY2019 · NS · contact PI
Immune-mediated therapies in a genetically engineered murine model of diffuse intrinsic pontine glioma$442,283
R21 · FY2019 · NS · contact PI
Cancer Biology Training Program$346,067
T32 · FY2019 · CA · contact PI
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics$462,618
R01 · FY2018 · NS · contact PI
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies$403,749
R37 · FY2018 · NS · contact PI
Cancer Biology Training Program$317,918
T32 · FY2018 · CA · contact PI
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies$403,749
R37 · FY2017 · NS · contact PI
Cancer Biology Training Program$328,219
T32 · FY2017 · CA · contact PI
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies$403,749
R37 · FY2016 · NS · contact PI
HDL-Loaded Nanoparticles for Glioma Therapeutics$232,500
R21 · FY2016 · NS · contact PI
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies$395,960
R37 · FY2015 · NS · contact PI
Crosstalk between glioma cells & immune cells in the tumor microenvironment: Ther$374,910
R01 · FY2015 · NS · contact PI
HDL-Loaded Nanoparticles for Glioma Therapeutics$194,010
R21 · FY2015 · NS · contact PI
Crosstalk between glioma cells & immune cells in the tumor microenvironment: Ther$371,734
R01 · FY2014 · NS · contact PI
Engineering the Brain Immune System for Tumor Therapy$367,641
R01 · FY2013 · NS · contact PI
Crosstalk between glioma cells & immune cells in the tumor microenvironment: Ther$362,892
R01 · FY2013 · NS · contact PI
Crosstalk between glioma cells & immune cells in the tumor microenvironment: Ther$382,781
R01 · FY2012 · NS · contact PI
Engineering the Brain Immune System for Tumor Therapy$380,975
R01 · FY2012 · NS · contact PI
Gutless Adenovirus Mediated Gene Therapy for Glioma$633,279
U01 · FY2011 · NS · contact PI
Crosstalk between glioma cells & immune cells in the tumor microenvironment: Ther$408,374
R01 · FY2011 · NS · contact PI
Engineering the Brain Immune System for Tumor Therapy$206,100
R01 · FY2011 · NS · contact PI
Engineering the Brain Immune System for Tumor Therapy$192,025
R01 · FY2011 · NS · contact PI
Gutless Adenovirus Mediated Gene Therapy for Glioma$623,550
U01 · FY2010 · NS · contact PI
Engineering the Brain Immune System for Tumor Therapy$402,188
R01 · FY2010 · NS · contact PI
Gutless Adenovirus Mediated Gene Therapy for Glioma$71,831
U01 · FY2010 · NS · contact PI
Gutless Adenovirus Mediated Gene Therapy for Glioma$698,252
U01 · FY2009 · NS · contact PI
Engineering the Brain Immune System for Tumor Therapy$406,250
R01 · FY2009 · NS · contact PI
Gutless Adenovirus Mediated Gene Therapy for Glioma$517,296
U01 · FY2008 · NS · contact PI
Targeted Toxin for Brain Cancer Gene Therapy$208,688
R21 · FY2008 · NS · contact PI
Gutless Adenovirus Mediated Gene Therapy for Glioma$532,528
U01 · FY2007 · NS · contact PI
Targeted Toxin for Brain Cancer Gene Therapy$173,906
R21 · FY2007 · NS · contact PI
Gene therapy for chronic neurodegenerative disorders$436,043
R01 · FY2006 · NS · contact PI
APOPTOSIS OF ANTERIOR PITUITARY CELLS$33,592
R03 · FY2006 · TW · contact PI
Gene therapy for chronic neurodegenerative disorders$443,008
R01 · FY2005 · NS
Gene therapy for chronic neurodegenerative disorders$37,251
R01 · FY2005 · NS
APOPTOSIS OF ANTERIOR PITUITARY CELLS$34,400
R03 · FY2005 · TW
Gene therapy for chronic neurodegenerative disorders$363,375
R01 · FY2004 · NS
APOPTOSIS OF ANTERIOR PITUITARY CELLS$34,400
R03 · FY2004 · TW
Gene therapy for chronic neurodegenerative disorders$363,375
R01 · FY2003 · NS
Gene therapy for chronic neurodegenerative disorders$363,375
R01 · FY2002 · NS